Based on an award-winning presentation. Lei Chen, co-founder and CTO at Rarity Bioscience, presents at the ASH Annual Meeting 2023!
He will host a scientific workshop expanding on Molecular MRD and the superRCA technology: “Ultra-Sensitive Molecular MRD on Flow Cytometer Using superRCA Mutation Assay”.
In the upcoming workshop, you will gain insights into the superRCA assay and why it can reach such high sensitivity and its remarkable ability to detect single nucleotide mutations at ultra-high sensitivity in a cohort of AML and MDS Minimal Residual Disease (MRD) patients, often with 10 to 100 times higher sensitivity than NGS and ddPCR.
From the abstract:
”Our superRCA (sRCA) assay is capable of detecting single nucleotide mutations at 1 in 100,000 sensitivity and the whole assay is configured as a single tube assay with serial solution addition, which makes it very convenient to work with and automate using available robotics platforms. We are now proving the utility of this ultra sensitive assay with malignant hematologies and using this ’flow based molecular MRD’ to complement the conventional ’flow based phenotypic MRD’, using the same flow cytometer.”
Welcome to attend the workshop!
If you are attending ASH, be sure not to miss the workshop. Additionally, say hello or schedule a meeting with our CEO, Linus Bosaeus, and our CTO, Lei Chen – they’ll be around for the whole conference!